A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy
ConclusionsBumetanide might be an effective and relatively tolerable drug in patients with drug-resistant TLE. Downregulation of NKCC1 protein following bumetanide treatment may be responsible for its antiepileptic effects.Iranian Registry of Clinical Trials IdentifierIRCT 201012115368N1.
Source: CNS Drugs - Category: Neurology Source Type: research
More News: Anorexia | Bumetanide | Chloride | Clinical Trials | Eating Disorders & Weight Management | Epilepsy | Genetics | Headache | Iran Health | Migraine | Neurology | Study